JP5897035B2 - 汎用の抗タグキメラ抗原受容体発現ｔ細胞及びがんを治療する方法 - Google Patents

汎用の抗タグキメラ抗原受容体発現ｔ細胞及びがんを治療する方法 Download PDF

Info

Publication number
JP5897035B2
JP5897035B2 JP2013544725A JP2013544725A JP5897035B2 JP 5897035 B2 JP5897035 B2 JP 5897035B2 JP 2013544725 A JP2013544725 A JP 2013544725A JP 2013544725 A JP2013544725 A JP 2013544725A JP 5897035 B2 JP5897035 B2 JP 5897035B2
Authority
JP
Japan
Prior art keywords
cells
car
fitc
cell
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2013544725A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014504294A (ja
JP2014504294A5 (cg-RX-API-DMAC7.html
Inventor
エドゥアルド ダヴィラ
エドゥアルド ダヴィラ
耕治 玉田
耕治 玉田
Original Assignee
ユニバーシティ オブ メリーランド，ボルチモア
ユニバーシティ オブ メリーランド，ボルチモア
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46245339&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP5897035(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by ユニバーシティ オブ メリーランド，ボルチモア, ユニバーシティ オブ メリーランド，ボルチモア filed Critical ユニバーシティ オブ メリーランド，ボルチモア
Publication of JP2014504294A publication Critical patent/JP2014504294A/ja
Publication of JP2014504294A5 publication Critical patent/JP2014504294A5/ja
Application granted granted Critical
Publication of JP5897035B2 publication Critical patent/JP5897035B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4203—Receptors for growth factors
    • A61K40/4204—Epidermal growth factor receptors [EGFR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4203—Receptors for growth factors
    • A61K40/4205—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ ErbB4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/555—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound pre-targeting systems involving an organic compound, other than a peptide, protein or antibody, for targeting specific cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6859—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from liver or pancreas cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6863—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from stomach or intestines cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • A61K47/6897—Pre-targeting systems with two or three steps using antibody conjugates; Ligand-antiligand therapies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/50—Colon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/54—Pancreas
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/515—CD3, T-cell receptor complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • General Engineering & Computer Science (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2013544725A 2010-12-14 2011-12-14 汎用の抗タグキメラ抗原受容体発現ｔ細胞及びがんを治療する方法 Active JP5897035B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US42268110P 2010-12-14 2010-12-14
US61/422,681 2010-12-14
PCT/US2011/064808 WO2012082841A2 (en) 2010-12-14 2011-12-14 Universal anti-tag chimeric antigen receptor-expressing t cells and methods of treating cancer

Publications (3)

Publication Number Publication Date
JP2014504294A JP2014504294A (ja) 2014-02-20
JP2014504294A5 JP2014504294A5 (cg-RX-API-DMAC7.html) 2014-07-10
JP5897035B2 true JP5897035B2 (ja) 2016-03-30

Family

ID=46245339

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013544725A Active JP5897035B2 (ja) 2010-12-14 2011-12-14 汎用の抗タグキメラ抗原受容体発現ｔ細胞及びがんを治療する方法

Country Status (7)

Country Link
US (4) US9233125B2 (cg-RX-API-DMAC7.html)
EP (2) EP2651442B1 (cg-RX-API-DMAC7.html)
JP (1) JP5897035B2 (cg-RX-API-DMAC7.html)
AU (1) AU2011343887B2 (cg-RX-API-DMAC7.html)
CA (2) CA2821080C (cg-RX-API-DMAC7.html)
ES (1) ES2791716T3 (cg-RX-API-DMAC7.html)
WO (1) WO2012082841A2 (cg-RX-API-DMAC7.html)

Families Citing this family (253)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100908114B1 (ko) * 2002-03-09 2009-07-16 삼성전자주식회사 스케일러블 무손실 오디오 부호화/복호화 장치 및 그 방법
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
EP2651442B1 (en) 2010-12-14 2020-04-22 University of Maryland, Baltimore Universal anti-tag chimeric antigen receptor-expressing t cells and methods of treating cancer
PL3246416T3 (pl) 2011-04-15 2024-09-30 The Johns Hopkins University Bezpieczny system sekwencjonowania
US9708384B2 (en) 2011-09-22 2017-07-18 The Trustees Of The University Of Pennsylvania Universal immune receptor expressed by T cells for the targeting of diverse and multiple antigens
EP3563872A1 (en) 2012-04-05 2019-11-06 Massachusetts Institute Of Technology Immunostimulatory compositions and methods of use thereof
CN104884095A (zh) * 2012-07-13 2015-09-02 宾夕法尼亚大学董事会 Cart19用于耗减正常b细胞以诱导耐受的用途
EP2872218A4 (en) * 2012-07-13 2016-07-06 Univ Pennsylvania COMPOSITIONS AND METHOD FOR REGULATING HAIR GROWTH
CA2889937C (en) 2012-10-29 2020-12-29 The Johns Hopkins University Papanicolaou test for ovarian and endometrial cancers
ES2776698T3 (es) * 2012-12-20 2020-07-31 Purdue Research Foundation Células T que expresan un receptor antigénico quimérico como terapia contra el cáncer
EP2958942B1 (en) 2013-02-20 2020-06-03 Novartis AG Effective targeting of primary human leukemia using anti-cd123 chimeric antigen receptor engineered t cells
ES2760023T3 (es) 2013-02-20 2020-05-12 Univ Pennsylvania Tratamiento del cáncer utilizando receptor de antígeno quimérico anti-EGFRvIII humanizado
EP3811954A1 (en) 2013-02-26 2021-04-28 Memorial Sloan Kettering Cancer Center Compositions and methods for immunotherapy
CN105358156A (zh) * 2013-03-13 2016-02-24 密执安大学评议会 双重mek/pi3k抑制剂和使用其的治疗方法
SG11201506974XA (en) * 2013-03-14 2015-10-29 Bellicum Pharmaceuticals Inc Methods for controlling t cell proliferation
US9499855B2 (en) 2013-03-14 2016-11-22 Elwha Llc Compositions, methods, and computer systems related to making and administering modified T cells
US9587237B2 (en) 2013-03-14 2017-03-07 Elwha Llc Compositions, methods, and computer systems related to making and administering modified T cells
EP2970426B1 (en) 2013-03-15 2019-08-28 Michael C. Milone Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
UY35468A (es) 2013-03-16 2014-10-31 Novartis Ag Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19
US10208125B2 (en) 2013-07-15 2019-02-19 University of Pittsburgh—of the Commonwealth System of Higher Education Anti-mucin 1 binding agents and uses thereof
WO2015017214A1 (en) * 2013-07-29 2015-02-05 Bluebird Bio, Inc. Multipartite signaling proteins and uses thereof
ES2741308T3 (es) * 2013-10-15 2020-02-10 Scripps Research Inst Interruptores de células T con receptores de antígenos quiméricos y usos de los mismos
ES2845924T3 (es) * 2013-10-15 2021-07-28 Scripps Research Inst Interruptores de células T con receptores de antígenos quiméricos peptídicos y usos de los mismos
RU2714902C2 (ru) 2013-12-19 2020-02-20 Новартис Аг Химерные рецепторы антигена против мезотелина человека и их применение
CA2933707A1 (en) * 2013-12-20 2015-06-25 Fred Hutchinson Cancer Research Center Tagged chimeric effector molecules and receptors thereof
EP3087101B1 (en) 2013-12-20 2024-06-05 Novartis AG Regulatable chimeric antigen receptor
EP4303229A3 (en) 2014-01-21 2024-04-17 Novartis AG Enhanced antigen presenting ability of car t cells by co-introduction of costimulatory molecules
CN106132423B (zh) 2014-02-14 2020-07-31 贝里坤制药股份有限公司 用诱导型嵌合多肽活化t细胞的方法
WO2015143224A1 (en) * 2014-03-19 2015-09-24 Ambrx, Inc. Chimeric antigen receptor-modified t-cells
ES2876263T3 (es) 2014-04-07 2021-11-12 Novartis Ag Tratamiento del cáncer usando receptor de antígeno quimérico anti-cd19
US11030531B2 (en) 2014-06-06 2021-06-08 Trustees Of Boston University DNA recombinase circuits for logical control of gene expression
CN105194661B (zh) * 2014-06-26 2019-05-03 科济生物医药（上海）有限公司 时空可调性抑制病理性靶细胞的系统
SG11201700416TA (en) 2014-07-21 2017-02-27 Novartis Ag Treatment of cancer using a cd33 chimeric antigen receptor
EP3171882A1 (en) 2014-07-21 2017-05-31 Novartis AG Treatment of cancer using a cll-1 chimeric antigen receptor
US11542488B2 (en) 2014-07-21 2023-01-03 Novartis Ag Sortase synthesized chimeric antigen receptors
US10174095B2 (en) 2014-07-21 2019-01-08 Novartis Ag Nucleic acid encoding a humanized anti-BCMA chimeric antigen receptor
WO2016012623A1 (en) * 2014-07-25 2016-01-28 Theravectys Lentiviral vectors for regulated expression of a chimeric antigen receptor molecule
DK3183268T3 (da) 2014-08-19 2020-05-11 Univ Pennsylvania Behandling af cancer ved anvendelse af en cd123-kimær antigenreceptor
ES2688035T3 (es) * 2014-08-29 2018-10-30 Gemoab Monoclonals Gmbh Receptor de antígeno universal que expresa células inmunes para direccionamiento de antígenos múltiples diversos, procedimiento para fabricación del mismo y utilización del mismo para tratamiento de cáncer, infecciones y enfermedades autoinmunes
EP3189148A4 (en) 2014-09-02 2018-05-02 Bellicum Pharmaceuticals, Inc. Costimulation of chimeric antigen receptors by myd88 and cd40 polypeptides
KR20210149228A (ko) 2014-09-17 2021-12-08 노파르티스 아게 입양 면역요법을 위한 키메라 수용체에 의한 세포독성 세포의 표적화
US10774388B2 (en) 2014-10-08 2020-09-15 Novartis Ag Biomarkers predictive of therapeutic responsiveness to chimeric antigen receptor therapy and uses thereof
DK3597742T3 (da) * 2014-10-09 2022-10-03 Univ Yamaguchi Car-udtrykkende vektor og car-udtrykkende t-celler
EP3025719B1 (en) 2014-11-26 2018-09-26 Miltenyi Biotec GmbH Combination immunotherapy of antigen-recognizing receptors and hematopoietic cells for the treatment of diseases
RU2751362C2 (ru) 2014-12-29 2021-07-13 Новартис Аг Способы получения экспрессирующих химерный антигенный рецептор клеток
US11459390B2 (en) 2015-01-16 2022-10-04 Novartis Ag Phosphoglycerate kinase 1 (PGK) promoters and methods of use for expressing chimeric antigen receptor
WO2016126608A1 (en) 2015-02-02 2016-08-11 Novartis Ag Car-expressing cells against multiple tumor antigens and uses thereof
IL254141B (en) 2015-02-27 2022-07-01 Icell Gene Therapeutics Llc Chimeric antigen receptors (cars) focusing on hematological malignancies, preparations and methods for their use
WO2016154621A1 (en) 2015-03-26 2016-09-29 The California Institute For Biomedical Research SWITCHABLE NON-scFv CHIMERIC RECEPTORS, SWITCHES, AND USES THEREOF
ES2904573T3 (es) * 2015-03-27 2022-04-05 Univ Southern California Terapia con células T dirigida a LHR para el tratamiento de tumores sólidos
HUE059218T2 (hu) 2015-04-08 2022-11-28 Novartis Ag CD20-terápiák, CD22-terápiák és kombinációs terápiák CD19 kiméra antigénreceptort (CAR-t) expresszáló sejttel
EP3283113A4 (en) * 2015-04-15 2018-12-05 The California Institute for Biomedical Research Optimized pne-based chimeric receptor t cell switches and uses thereof
US11896614B2 (en) 2015-04-17 2024-02-13 Novartis Ag Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells
EP3286211A1 (en) 2015-04-23 2018-02-28 Novartis AG Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
EP3288570A4 (en) 2015-04-29 2018-11-21 Fred Hutchinson Cancer Research Center Modified stem cells and uses thereof
US11173179B2 (en) 2015-06-25 2021-11-16 Icell Gene Therapeutics Llc Chimeric antigen receptor (CAR) targeting multiple antigens, compositions and methods of use thereof
TW202444897A (zh) 2015-06-25 2024-11-16 美商生物細胞基因治療有限公司 嵌合抗原受體(car)、組合物及其使用方法
SG10201912978PA (en) 2015-07-21 2020-02-27 Novartis Ag Methods for improving the efficacy and expansion of immune cells
WO2017027392A1 (en) 2015-08-07 2017-02-16 Novartis Ag Treatment of cancer using chimeric cd3 receptor proteins
US11286531B2 (en) 2015-08-11 2022-03-29 The Johns Hopkins University Assaying ovarian cyst fluid
KR102157701B1 (ko) * 2015-08-17 2020-09-21 서울대학교산학협력단 항-코티닌 항체가 연결된 키메라 항체 수용체 및 이의 용도
US20180243340A1 (en) * 2015-08-24 2018-08-30 University Of Houston System Combination therapy combining car + t cells with appropriately timed immunodulatory antibodies
CN108780084B (zh) 2015-09-03 2022-07-22 诺华股份有限公司 预测细胞因子释放综合征的生物标志物
CN108350462B (zh) 2015-09-11 2022-05-27 生物权威（英国）有限公司 嵌合抗原受体及其用途
EP3352784A4 (en) 2015-09-23 2019-06-26 Cytoimmune Therapeutics, LLC FLT3-FACED CAR CELLS FOR IMMUNOTHERAPY
US12241053B2 (en) 2015-10-09 2025-03-04 The Brigham And Women's Hospital, Inc. Modulation of novel immune checkpoint targets
WO2017075465A1 (en) 2015-10-28 2017-05-04 The Broad Institute Inc. Compositions and methods for evaluating and modulating immune responses by detecting and targeting gata3
WO2017075451A1 (en) 2015-10-28 2017-05-04 The Broad Institute Inc. Compositions and methods for evaluating and modulating immune responses by detecting and targeting pou2af1
WO2017087708A1 (en) 2015-11-19 2017-05-26 The Brigham And Women's Hospital, Inc. Lymphocyte antigen cd5-like (cd5l)-interleukin 12b (p40) heterodimers in immunity
EP3380602A4 (en) * 2015-11-23 2019-09-25 Trustees of Boston University METHOD AND COMPOSITIONS RELATED TO CHIMERIC ANTIGEN RECEPTORS
CN108699557B (zh) 2015-12-04 2025-08-15 诺华股份有限公司 用于免疫肿瘤学的组合物和方法
WO2017112784A1 (en) * 2015-12-22 2017-06-29 The Trustees Of The University Of Pennsylvania Spycatcher and spytag: universal immune receptors for t cells
US20180371052A1 (en) * 2015-12-22 2018-12-27 Icell Gene Therapeutics Llc Chimeric antigen receptors and enhancement of anti-tumor activity
EP4643874A2 (en) 2015-12-22 2025-11-05 Novartis AG Mesothelin chimeric antigen receptor (car) and antibody against pd-l1 inhibitor for combined use in anticancer therapy
CN108473959B (zh) * 2016-01-20 2023-04-21 菲特治疗公司 用来在过继性免疫疗法中进行免疫细胞调节的组合物和方法
EP3405568A4 (en) 2016-01-20 2019-12-04 Fate Therapeutics, Inc. COMPOUNDS AND METHODS FOR IMMUNOCELL MODULATION IN ADOPTIVE IMMUNOTHERAPIES
JP2019508036A (ja) * 2016-02-16 2019-03-28 ダナ−ファーバー キャンサー インスティテュート，インコーポレイテッド 免疫療法組成物及び方法
KR102186180B1 (ko) * 2016-03-17 2020-12-03 고쿠리츠다이가쿠호우진 야마구치 다이가쿠 면역 기능 제어 인자를 발현하는 면역 담당 세포 및 발현 벡터
WO2017165683A1 (en) 2016-03-23 2017-09-28 Novartis Ag Cell secreted minibodies and uses thereof
JP7282521B2 (ja) * 2016-04-08 2023-05-29 パーデュー・リサーチ・ファウンデイション Ｃａｒ ｔ細胞療法のための方法および組成物
WO2017192536A1 (en) 2016-05-02 2017-11-09 University Of Kansas Eliminating mhc restriction from the t cell receptor as a strategy for immunotherapy
US20200283534A1 (en) 2016-06-24 2020-09-10 iCell Gene Therapeuticics LLC CHIMERIC ANTIGEN RECEPTORS (CARs), COMPOSITIONS AND METHODS THEREOF
WO2018049025A2 (en) 2016-09-07 2018-03-15 The Broad Institute Inc. Compositions and methods for evaluating and modulating immune responses
WO2018067991A1 (en) 2016-10-07 2018-04-12 The Brigham And Women's Hospital, Inc. Modulation of novel immune checkpoint targets
CA3039646A1 (en) 2016-10-07 2018-04-12 Novartis Ag Chimeric antigen receptors for the treatment of cancer
AU2017345479B2 (en) 2016-10-19 2024-03-21 The Scripps Research Institute Chimeric antigen receptor effector cell switches with humanized targeting moieties and/or optimized chimeric antigen receptor interacting domains and uses thereof
US10617720B2 (en) 2016-10-20 2020-04-14 Miltenyi Biotech, GmbH Chimeric antigen receptor specific for tumor cells
EP3315511A1 (en) 2016-10-29 2018-05-02 Miltenyi Biotec GmbH Adapter chimeric antigen receptor expressing cells for targeting of multiple antigens
WO2018089386A1 (en) 2016-11-11 2018-05-17 The Broad Institute, Inc. Modulation of intestinal epithelial cell differentiation, maintenance and/or function through t cell action
US11261428B2 (en) 2018-03-15 2022-03-01 KSQ Therapeutics, Inc. Gene-regulating compositions and methods for improved immunotherapy
US11332713B2 (en) 2016-11-16 2022-05-17 KSQ Therapeutics, Inc. Gene-regulating compositions and methods for improved immunotherapy
EP3336107A1 (en) 2016-12-15 2018-06-20 Miltenyi Biotec GmbH Immune cells expressing an antigen binding receptor and a chimeric costimulatory receptor
KR102122546B1 (ko) * 2017-01-05 2020-06-15 한국생명공학연구원 항-코티닌 키메릭 항원 수용체를 발현하는 자연살해 세포
CN110475857B (zh) 2017-01-05 2023-07-18 韩国生命工学研究院 表达抗-可替宁嵌合抗原受体的天然杀伤细胞
EP3574005B1 (en) 2017-01-26 2021-12-15 Novartis AG Cd28 compositions and methods for chimeric antigen receptor therapy
US11649288B2 (en) 2017-02-07 2023-05-16 Seattle Children's Hospital Phospholipid ether (PLE) CAR T cell tumor targeting (CTCT) agents
EP4353818A3 (en) 2017-02-27 2024-06-19 Juno Therapeutics, Inc. Compositions, articles of manufacture and methods related to dosing in cell therapy
WO2018160622A1 (en) 2017-02-28 2018-09-07 Endocyte, Inc. Compositions and methods for car t cell therapy
CN110832075A (zh) 2017-03-22 2020-02-21 诺华股份有限公司 用于免疫肿瘤学的组合物和方法
WO2018183908A1 (en) 2017-03-31 2018-10-04 Dana-Farber Cancer Institute, Inc. Compositions and methods for treating ovarian tumors
WO2018183921A1 (en) 2017-04-01 2018-10-04 The Broad Institute, Inc. Methods and compositions for detecting and modulating an immunotherapy resistance gene signature in cancer
AU2018250336B2 (en) 2017-04-07 2025-02-20 Juno Therapeutics, Inc. Engineered cells expressing prostate-specific membrane antigen (PSMA) or a modified form thereof and related methods
US20200071773A1 (en) 2017-04-12 2020-03-05 Massachusetts Eye And Ear Infirmary Tumor signature for metastasis, compositions of matter methods of use thereof
CN110709700A (zh) 2017-04-14 2020-01-17 朱诺治疗学股份有限公司 评估细胞表面糖基化的方法
AU2018256436B2 (en) 2017-04-19 2024-12-05 Board Of Regents, The University Of Texas System Immune cells expressing engineered antigen receptors
WO2018209324A2 (en) 2017-05-11 2018-11-15 The Broad Institute, Inc. Methods and compositions of use of cd8+ tumor infiltrating lymphocyte subtypes and gene signatures thereof
CA3065133A1 (en) 2017-06-09 2018-12-13 Gemoab Monoclonals Gmbh Targeting modules for universal chimeric antigen receptor expressing immune cells and use in the treatment of cancer, infections and autoimmune disorders
US11897953B2 (en) 2017-06-14 2024-02-13 The Broad Institute, Inc. Compositions and methods targeting complement component 3 for inhibiting tumor growth
US12275787B2 (en) 2017-06-21 2025-04-15 Icell Gene Therapeutics Llc Chimeric antigen receptors (CARs), compositions and methods thereof
US12049643B2 (en) 2017-07-14 2024-07-30 The Broad Institute, Inc. Methods and compositions for modulating cytotoxic lymphocyte activity
WO2019067092A1 (en) 2017-08-07 2019-04-04 The Johns Hopkins University METHODS AND SUBSTANCES FOR THE EVALUATION AND TREATMENT OF CANCER
KR20200055037A (ko) * 2017-09-19 2020-05-20 메사추세츠 인스티튜트 오브 테크놀로지 키메라 항원 수용체 t 세포 요법을 위한 조성물 및 그의 용도
WO2019070755A1 (en) 2017-10-02 2019-04-11 The Broad Institute, Inc. METHODS AND COMPOSITIONS FOR DETECTING AND MODULATING A GENETIC SIGNATURE OF IMMUNOTHERAPY RESISTANCE IN CANCER
CA3079407A1 (en) 2017-10-18 2019-04-25 Novartis Ag Compositions and methods for selective protein degradation
WO2019084055A1 (en) 2017-10-23 2019-05-02 Massachusetts Institute Of Technology CLASSIFICATION OF GENETIC VARIATION FROM UNICELLULAR TRANSCRIPTOMS
US11117936B2 (en) 2017-11-10 2021-09-14 University of Pittsburg—Of the Commonwealth System of Higher Education Affinity-enhanced monomeric streptavidin chimeric antigen receptor (CAR)
WO2019094955A1 (en) 2017-11-13 2019-05-16 The Broad Institute, Inc. Methods and compositions for targeting developmental and oncogenic programs in h3k27m gliomas
WO2019094983A1 (en) 2017-11-13 2019-05-16 The Broad Institute, Inc. Methods and compositions for treating cancer by targeting the clec2d-klrb1 pathway
EP3744738A4 (en) * 2017-11-29 2021-12-15 Guangzhou Cas Lamvac Biotech Co., Ltd. CHEMERICAL ANTIGENIC RECEPTOR AND RELATED APPLICATION
EP3723787A4 (en) 2017-12-14 2021-09-01 Bluebird Bio, Inc. DARIC INTERLEUKIN RECEPTORS
CN111542547B (zh) 2018-01-04 2024-02-13 美天施生物科技有限两合公司 对bdca2抗原具有特异性的嵌合抗原受体
US11994512B2 (en) 2018-01-04 2024-05-28 Massachusetts Institute Of Technology Single-cell genomic methods to generate ex vivo cell systems that recapitulate in vivo biology with improved fidelity
KR102795692B1 (ko) 2018-01-19 2025-04-16 밀테니 비오텍 비.브이. & 씨오. 케이지 키메라 항원 수용체를 발현하는 조절 t 세포
CN112292138A (zh) 2018-01-22 2021-01-29 西雅图儿童医院（Dba西雅图儿童研究所） Car t细胞的使用方法
SG11202007426XA (en) 2018-02-06 2020-09-29 Seattle Childrens Hospital Dba Seattle Childrens Res Inst Fluorescein-specific cars exhibiting optimal t cell function against fl-ple labelled tumors
EP3755349A4 (en) 2018-02-21 2021-11-17 Board of Regents, The University of Texas System PROCESS FOR ACTIVATION AND EXPANSION OF NATURAL KILLER CELLS AND THEIR USES
WO2019165237A1 (en) 2018-02-23 2019-08-29 Endocyte, Inc. Sequencing method for car t cell therapy
CA3091138A1 (en) 2018-02-26 2019-08-29 Fred Hutchinson Cancer Research Center Compositions and methods for cellular immunotherapy
KR20210006330A (ko) 2018-03-01 2021-01-18 유니버시티 오브 캔사스 재조합 t 세포 수용체 유전자를 사용하여 세포-기반 치료제를 생성하는 기술
JP7558563B2 (ja) 2018-03-15 2024-10-01 ケーエスキュー セラピューティクス， インコーポレイテッド 免疫療法の改善のための遺伝子調節組成物及び遺伝子調節方法
WO2019195586A1 (en) 2018-04-06 2019-10-10 The Regents Of The University Of California Methods of treating egfrviii expressing glioblastomas
WO2019195596A1 (en) 2018-04-06 2019-10-10 The Regents Of The University Of California Methods of treating glioblastomas
US20210155986A1 (en) 2018-04-13 2021-05-27 The Johns Hopkins University Non-invasive detection of response to immunotherapy
US20210079384A1 (en) 2018-04-13 2021-03-18 The Johns Hopkins University Non-invasive detection of response to a targeted therapy
US11957695B2 (en) 2018-04-26 2024-04-16 The Broad Institute, Inc. Methods and compositions targeting glucocorticoid signaling for modulating immune responses
WO2019217913A1 (en) 2018-05-10 2019-11-14 Sensei Biotherapeutics, Inc. Aspartate beta-hydroxylase chimeric antigen receptors and uses thereof
CN112805563B (zh) 2018-05-18 2025-06-13 约翰·霍普金斯大学 用于评估和/或治疗癌症的无细胞dna
WO2019222642A1 (en) * 2018-05-18 2019-11-21 Senti Biosciences, Inc. Engineered immune cells and methods of use
WO2019232542A2 (en) 2018-06-01 2019-12-05 Massachusetts Institute Of Technology Methods and compositions for detecting and modulating microenvironment gene signatures from the csf of metastasis patients
EP3806888B1 (en) 2018-06-12 2024-01-31 Obsidian Therapeutics, Inc. Pde5 derived regulatory constructs and methods of use in immunotherapy
MY208825A (en) 2018-06-13 2025-05-30 Novartis Ag Bcma chimeric antigen receptors and uses thereof
EP3581200A1 (en) 2018-06-13 2019-12-18 GEMoaB Monoclonals GmbH Reversed universal chimeric antigen receptor expressing immune cells for targeting of diverse multiple antigens and method of manufacturing the same and use of the same for treatment of cancer, infections and autoimmune disorders
US12036240B2 (en) 2018-06-14 2024-07-16 The Broad Institute, Inc. Compositions and methods targeting complement component 3 for inhibiting tumor growth
US12466869B2 (en) 2018-06-28 2025-11-11 Dana-Farber Cancer Institute, Inc. Targeting of multiple antigens with multiplex CAR T cells in solid and liquid malignancies
WO2020010229A1 (en) * 2018-07-06 2020-01-09 Arizona Board Of Regents On Behalf Of The University Of Arizona Car t cell therapy to target t cell specific cancers
WO2020033927A2 (en) 2018-08-09 2020-02-13 Juno Therapeutics, Inc. Processes for generating engineered cells and compositions thereof
CN110856724B (zh) * 2018-08-24 2022-05-27 杭州康万达医药科技有限公司 包含核酸及car修饰的免疫细胞的治疗剂及其应用
EP3620464A1 (en) 2018-09-10 2020-03-11 Miltenyi Biotec GmbH Car cell having crosslinked disulfide bridge on antigen recognizing moiety
JP7504891B2 (ja) 2018-09-11 2024-06-24 ジュノー セラピューティクス インコーポレイテッド 操作された細胞組成物のマススペクトロメトリー分析のための方法
KR20210068478A (ko) 2018-09-28 2021-06-09 메사추세츠 인스티튜트 오브 테크놀로지 콜라겐-국재화된 면역조정성 분자 및 그의 방법
US20210382068A1 (en) 2018-10-02 2021-12-09 Dana-Farber Cancer Institute, Inc. Hla single allele lines
US20220267435A1 (en) * 2018-10-03 2022-08-25 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Covalent adaptor synnotch and chimeric antigen receptors (cars) for programmable antigen-targeting
US20210379057A1 (en) 2018-10-16 2021-12-09 Massachusetts Institute Of Technology Nutlin-3a for use in treating a mycobacterium tuberculosis infection
WO2020086742A1 (en) 2018-10-24 2020-04-30 Obsidian Therapeutics, Inc. Er tunable protein regulation
US20220170097A1 (en) * 2018-10-29 2022-06-02 The Broad Institute, Inc. Car t cell transcriptional atlas
CA3117568A1 (en) 2018-10-31 2020-05-07 Juno Therapeutics Gmbh Methods for selection and stimulation of cells and apparatus for same
US12291560B2 (en) 2018-12-14 2025-05-06 Regeneron Pharmaceuticals, Inc. Dimerizing agent regulated immunoreceptor complexes
WO2020131586A2 (en) 2018-12-17 2020-06-25 The Broad Institute, Inc. Methods for identifying neoantigens
US11739156B2 (en) 2019-01-06 2023-08-29 The Broad Institute, Inc. Massachusetts Institute of Technology Methods and compositions for overcoming immunosuppression
CN111454909B (zh) * 2019-01-22 2024-12-10 北京大学深圳研究生院 天然配体介导的多靶点识别可调控基因工程化免疫细胞的制备方法
CN113347991B (zh) 2019-01-23 2024-07-30 美天施生物科技有限两合公司 用于消除和增强受试者骨髓中造血干细胞植入的组合物的组合
US20220154282A1 (en) 2019-03-12 2022-05-19 The Broad Institute, Inc. Detection means, compositions and methods for modulating synovial sarcoma cells
EP3942023A1 (en) 2019-03-18 2022-01-26 The Broad Institute, Inc. Compositions and methods for modulating metabolic regulators of t cell pathogenicity
WO2020191305A2 (en) 2019-03-20 2020-09-24 Massachusetts Institute Of Technology Uses of amphiphiles in immune cell therapy and compositions therefor
EP3946382A1 (en) 2019-04-04 2022-02-09 UMC Utrecht Holding B.V. Modified immune receptor constructs
BR112021019571A2 (pt) 2019-04-19 2021-12-07 Chugai Pharmaceutical Co Ltd Receptor quimérico que reconhece o sítio de modificação do anticorpo
EP3962519A1 (en) 2019-05-01 2022-03-09 Juno Therapeutics, Inc. Cells expressing a chimeric receptor from a modified cd247 locus, related polynucleotides and methods
KR20220016475A (ko) 2019-05-01 2022-02-09 주노 쎄러퓨티크스 인코퍼레이티드 변형된 ｔｇｆｂｒ2 유전자 좌에서 재조합 수용체를 발현하는 세포, 관련 폴리뉴클레오티드 및 방법
MX2021013417A (es) 2019-05-04 2021-12-10 Inhibrx Inc Polipeptidos de union a la proteina del miembro a de la familia 12 del dominio de lectina tipo c (clec12a) y sus usos.
CN114502586B (zh) 2019-05-08 2025-06-24 瑞泽恩制药公司 Cll-1靶向免疫疗法
US20220235340A1 (en) 2019-05-20 2022-07-28 The Broad Institute, Inc. Novel crispr-cas systems and uses thereof
CA3142108A1 (en) 2019-05-28 2020-12-03 Miltenyi Biotec B.V. & Co. KG Method for generation of genetically modified t cells
WO2020243371A1 (en) 2019-05-28 2020-12-03 Massachusetts Institute Of Technology Methods and compositions for modulating immune responses
EP3990491A1 (en) 2019-06-26 2022-05-04 Massachusetts Institute of Technology Immunomodulatory fusion protein-metal hydroxide complexes and methods thereof
WO2021011781A1 (en) * 2019-07-16 2021-01-21 The Regents Of The University Of California Universal chimeric antigen receptors and methods for making and using them
WO2021030627A1 (en) 2019-08-13 2021-02-18 The General Hospital Corporation Methods for predicting outcomes of checkpoint inhibition and treatment thereof
US12421557B2 (en) 2019-08-16 2025-09-23 The Broad Institute, Inc. Methods for predicting outcomes and treating colorectal cancer using a cell atlas
US20220298501A1 (en) 2019-08-30 2022-09-22 The Broad Institute, Inc. Crispr-associated mu transposase systems
US20220348937A1 (en) 2019-09-06 2022-11-03 Obsidian Therapeutics, Inc. Compositions and methods for dhfr tunable protein regulation
US20220315894A1 (en) 2019-09-11 2022-10-06 Miltenyi Biotec B.V. & Co. KG Method for Transduction of T Cells in the Presence of Malignant Cells
WO2021061648A1 (en) 2019-09-23 2021-04-01 Massachusetts Institute Of Technology Methods and compositions for stimulation of endogenous t cell responses
US12297426B2 (en) 2019-10-01 2025-05-13 The Broad Institute, Inc. DNA damage response signature guided rational design of CRISPR-based systems and therapies
US12394502B2 (en) 2019-10-02 2025-08-19 The General Hospital Corporation Method for predicting HLA-binding peptides using protein structural features
US12195725B2 (en) 2019-10-03 2025-01-14 Dana-Farber Cancer Institute, Inc. Compositions and methods for modulating and detecting tissue specific TH17 cell pathogenicity
US11981922B2 (en) 2019-10-03 2024-05-14 Dana-Farber Cancer Institute, Inc. Methods and compositions for the modulation of cell interactions and signaling in the tumor microenvironment
US11793787B2 (en) 2019-10-07 2023-10-24 The Broad Institute, Inc. Methods and compositions for enhancing anti-tumor immunity by targeting steroidogenesis
CA3154281A1 (en) 2019-10-16 2021-04-22 Andrew Scharenberg Retroviral vector for universal receptor therapy
CA3151961A1 (en) * 2019-10-18 2021-04-22 Mohammadreza PAKYARI Cal-t constructs and uses thereof
US11844800B2 (en) 2019-10-30 2023-12-19 Massachusetts Institute Of Technology Methods and compositions for predicting and preventing relapse of acute lymphoblastic leukemia
PH12022551291A1 (en) 2019-11-26 2023-11-20 Novartis Ag Chimeric antigen receptors binding bcma and cd19 and uses thereof
IL292924A (en) 2019-11-26 2022-07-01 Novartis Ag Cd19 and cd22 chimeric antigen receptors and uses thereof
US12165747B2 (en) 2020-01-23 2024-12-10 The Broad Institute, Inc. Molecular spatial mapping of metastatic tumor microenvironment
EP4097218A1 (en) 2020-01-28 2022-12-07 Juno Therapeutics, Inc. Methods for t cell transduction
CN115066249A (zh) 2020-02-04 2022-09-16 美天施生物科技有限两合公司 表达用于感测可溶性抗原的适体嵌合抗原受体的免疫细胞
US20220073977A1 (en) 2020-02-14 2022-03-10 The Johns Hopkins University Methods and materials for assessing nucleic acids
EP3878464A1 (en) 2020-03-09 2021-09-15 Miltenyi Biotec B.V. & Co. KG Use of a car cell having crosslinked disulfide bridge on antigen recognizing moiety for targeting cancer cells
EP4118112A1 (en) 2020-03-10 2023-01-18 Massachusetts Institute of Technology Compositions and methods for immunotherapy of npm1c-positive cancer
KR20240096884A (ko) 2020-03-10 2024-06-26 매사추세츠 인스티튜트 오브 테크놀로지 조작된 기억-유사 nk 세포 및 이의 조성물을 생성하기 위한 방법
EP3881866A1 (en) 2020-03-16 2021-09-22 GEMoaB GmbH A targeting module comprising pd-l1 and/or pd-l2 for use in a method for stimulating a chimeric antigen receptor mediated response in a mammal
CN115397517A (zh) 2020-04-17 2022-11-25 希望之城 用于治疗flt3阳性恶性肿瘤的靶向flt3的嵌合抗原受体修饰细胞
US12433954B2 (en) 2020-05-01 2025-10-07 Massachusetts Institute Of Technology Methods of activating anti-CD19 chimeric antigen receptor (CAR) T cells using amphiphilic ligand conjugates comprising CAR-targeting protein sequence motifs
US20210340524A1 (en) 2020-05-01 2021-11-04 Massachusetts Institute Of Technology Methods for identifying chimeric antigen receptor-targeting ligands and uses thereof
US20230183372A1 (en) 2020-05-20 2023-06-15 Miltenyi Biotec B.V. & Co. KG Compositions and Methods for Treating Cancer Expressing CD90 and CD326
US12286465B2 (en) 2020-05-28 2025-04-29 Miltenyi Biotec B.V. & Co. KG Chimeric antigen receptor with a spacer comprising C2-set Ig-like domains
WO2021260186A1 (en) 2020-06-26 2021-12-30 Juno Therapeutics Gmbh Engineered t cells conditionally expressing a recombinant receptor, related polynucleotides and methods
WO2022015955A1 (en) 2020-07-16 2022-01-20 Umoja Biopharma, Inc. Gated adapter targeting receptor
AU2021317974A1 (en) 2020-07-31 2023-03-16 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical Composition comprising Cell Expressing Chimeric Receptor
WO2022038411A1 (en) 2020-08-19 2022-02-24 Astellas Pharma, Inc. Human non-naturally occurring modified fc region of igg specifically binding to non-naturally occurring modified fc receptor
EP3964585A1 (en) 2020-09-03 2022-03-09 Miltenyi Biotec B.V. & Co. KG Cd62l specific lentiviral vector particle for targeted transduction of t cell subsets
ES2994677T3 (en) * 2020-09-04 2025-01-29 Miltenyi Biotec Bv & Co Kg System for inducible expression of an adapter in immune cells
EP4228660A4 (en) * 2020-10-14 2025-02-26 Georgia Tech Research Corporation Synthetic antigens as chimeric antigen receptor (car) ligands and uses thereof
EP4240403A2 (en) 2020-11-04 2023-09-13 Miltenyi Biotec B.V. & Co. KG Chimeric antigen receptor comprising an antigen binding domain specific for msln having a specificity for tumor cells
US20230398148A1 (en) 2020-11-04 2023-12-14 Juno Therapeutics, Inc. Cells expressing a chimeric receptor from a modified invariant cd3 immunoglobulin superfamily chain locus and related polynucleotides and methods
WO2022096664A1 (en) 2020-11-09 2022-05-12 Miltenyi Biotec B.V. & Co. KG Methods and compositions for eliminating engineered immune cells
JP2024500847A (ja) * 2020-12-18 2024-01-10 センチュリー セラピューティクス，インコーポレイテッド 適合可能な受容体特異性を有するキメラ抗原受容体システム
KR20230159851A (ko) 2021-03-22 2023-11-22 주노 쎄러퓨티크스 인코퍼레이티드 치료 세포 조성물의 효력을 결정하는 방법
AU2022244229A1 (en) 2021-03-22 2023-09-14 Juno Therapeutics, Inc. Method to assess potency of viral vector particles
WO2022236096A1 (en) * 2021-05-07 2022-11-10 University Of Florida Research Foundation, Inc. Car t cell therapy method
CN117715655A (zh) * 2021-06-08 2024-03-15 生物技术细胞和基因治疗公司 用于活化和靶向免疫效应细胞的物质和方法
CA3227128A1 (en) * 2021-07-28 2023-02-02 Prescient Therapeutics Ltd Universal receptor immune cell therapy
US20250235477A1 (en) 2021-10-06 2025-07-24 Miltenyi Biotec B.V. & Co. KG Method for targeted gene insertion into immune cells
WO2023062113A1 (en) 2021-10-15 2023-04-20 Miltenyi Biotec B.V. & Co. KG Method for the generation of genetically modified nk cells
WO2023081715A1 (en) 2021-11-03 2023-05-11 Viracta Therapeutics, Inc. Combination of car t-cell therapy with btk inhibitors and methods of use thereof
EP4176895A1 (en) 2021-11-08 2023-05-10 AvenCell Europe GmbH Targeting modules against il13ra2 or her2 for use in combination with a chimeric antigen receptor
US11827716B2 (en) 2021-11-15 2023-11-28 Arcellx, Inc. D-domain containing polypeptides and uses thereof
WO2023107825A1 (en) * 2021-12-07 2023-06-15 The Regents Of The University Of California Synthetic cytokine circuits to promote infiltration and clearance of immune excluded solid tumors by engineered immune cells
CN118973608A (zh) 2022-04-01 2024-11-15 美天施生物科技有限两合公司 用于多核苷酸的药物诱导型表达的系统
EP4522751A1 (en) 2022-05-10 2025-03-19 Miltenyi Biotec B.V. & Co. KG Compositions comprising il-15, il-15 receptor alpha and the intracellular signaling domain of cd2 for immune cell therapy
WO2023224715A1 (en) 2022-05-19 2023-11-23 Massachusetts Institute Of Technology Car cells targeting an inserted ligand
WO2024077256A1 (en) 2022-10-07 2024-04-11 The General Hospital Corporation Methods and compositions for high-throughput discovery ofpeptide-mhc targeting binding proteins
WO2024078995A1 (en) 2022-10-15 2024-04-18 Miltenyi Biotec B.V. & Co. KG Transduction of gammadelta t cells with pseudotyped retroviral vectors
WO2024124044A1 (en) 2022-12-07 2024-06-13 The Brigham And Women’S Hospital, Inc. Compositions and methods targeting sat1 for enhancing anti¬ tumor immunity during tumor progression
CN116041545A (zh) * 2022-12-12 2023-05-02 南方医科大学 一种靶向荧光素或生物素的通用型car及其应用
WO2024178397A2 (en) 2023-02-24 2024-08-29 Elevatebio Technologies, Inc. Modified immune effector cells and methods of use
WO2024191918A1 (en) 2023-03-10 2024-09-19 The Regents Of The University Of Colorado, A Body Corporate Anti-cd276 and anti-cd99 logic gated chimeric antigen receptors for the treatment of cancer
WO2024191919A1 (en) 2023-03-10 2024-09-19 The Regents Of The University Of Colorado, A Body Corporate Anti-cd56 and anti-cd99 logic gated chimeric antigen receptors for the treatment of cancer
WO2024220588A1 (en) 2023-04-18 2024-10-24 Juno Therapeutics, Inc. Cytotoxicity assay for assessing potency of therapeutic cell compositions
AU2024261890A1 (en) 2023-04-27 2025-10-09 Miltenyi Biotec B.V. & Co. KG Retroviral vector particle pseudotyped with envelope proteins of canine distemper virus
WO2024223847A1 (en) 2023-04-27 2024-10-31 Miltenyi Biotec B.V. & Co. KG Pseudotyped retroviral vector particle with anti-cd3 display
US20250018037A1 (en) * 2023-05-19 2025-01-16 Seoul National University R&Db Foundation Safety control of switchable chimeric antigen receptor t cells using dose-adjustable adaptors
WO2024243365A2 (en) 2023-05-23 2024-11-28 Juno Therapeutics, Inc. Activation markers of t cells and method for assessing t cell activation
EP4470555A1 (en) 2023-05-31 2024-12-04 Miltenyi Biotec B.V. & Co. KG Anti-tag chimeric antigen receptors with specificity for mutated peptides derived from human fgfr2
EP4471067A1 (en) 2023-06-01 2024-12-04 Miltenyi Biotec B.V. & Co. KG A chemically inducible heterodimerizing system and a method for generation thereof
AU2024310260A1 (en) 2023-06-29 2025-12-11 Dispatch Biotherapeutics, Inc. Synthetic cytokine receptors
WO2025059533A1 (en) 2023-09-13 2025-03-20 The Broad Institute, Inc. Crispr enzymes and systems
WO2025078492A1 (en) 2023-10-13 2025-04-17 Miltenyi Biotec B.V. & Co. KG Cd3-targeted nipah-pseudotyped lentiviral vector particles
WO2025087935A1 (en) 2023-10-26 2025-05-01 Miltenyi Biotec B.V. & Co. KG Chimeric antigen receptor specific for folate receptor 1
WO2025097055A2 (en) 2023-11-02 2025-05-08 The Broad Institute, Inc. Compositions and methods of use of t cells in immunotherapy
WO2025117544A1 (en) 2023-11-29 2025-06-05 The Broad Institute, Inc. Engineered omega guide molecule and iscb compositions, systems, and methods of use thereof
WO2025125231A1 (en) 2023-12-11 2025-06-19 Miltenyi Biotec B.V. & Co. KG Antigen - induced secretion of effector molecules of car t cells
WO2025149431A1 (en) 2024-01-08 2025-07-17 Miltenyi Biotec B.V. & Co. KG Anti cd276 adapter chimeric antigen receptor (car)
WO2025252325A1 (en) 2024-06-06 2025-12-11 Miltenyi Biotec B.V. & Co. KG A human protein scaffold library based on the pdz3 domain of the tight junction protein zo-1
WO2025252326A1 (en) 2024-06-06 2025-12-11 Miltenyi Biotec B.V. & Co. KG A human protein scaffold library based on the n-terminal domain of human fact complex subunit ssrp1

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5906936A (en) 1988-05-04 1999-05-25 Yeda Research And Development Co. Ltd. Endowing lymphocytes with antibody specificity
US5861156A (en) 1993-01-08 1999-01-19 Creative Biomolecules Methods of delivering agents to target cells
US20090011984A1 (en) 1998-02-23 2009-01-08 Seppo Yla-Herttuala Biotin-binding receptor molecules
EP1064026A4 (en) 1998-03-10 2003-04-09 Univ Pennsylvania STRENGTHENING INTRA-CELLULAR ADMINISTRATION AND TARGETING SPECIFIC TISSUE OF MEDICINES AND GENES
JP2001213804A (ja) 2000-01-31 2001-08-07 Chugai Pharmaceut Co Ltd 抗組織因子抗体の複合体
AU2001271273A1 (en) 2000-05-24 2001-12-03 Ludwig Institute For Cancer Research Multicomponent conjugates which bind to target molecules and stimulate cell lysis
ES2304398T3 (es) 2000-07-31 2008-10-16 Green Peptide Co., Ltd. Antigeno de tumores.
US7514537B2 (en) * 2001-04-30 2009-04-07 City Of Hope Chimeric immunoreceptor useful in treating human gliomas
US7446190B2 (en) * 2002-05-28 2008-11-04 Sloan-Kettering Institute For Cancer Research Nucleic acids encoding chimeric T cell receptors
US20050129671A1 (en) * 2003-03-11 2005-06-16 City Of Hope Mammalian antigen-presenting T cells and bi-specific T cells
TWI342312B (en) 2003-10-22 2011-05-21 Theravance Inc Hydrochloride salts of a glycopeptide phosphonate derivative
US20050113564A1 (en) * 2003-11-05 2005-05-26 St. Jude Children's Research Hospital Chimeric receptors with 4-1BB stimulatory signaling domain
CN100376599C (zh) * 2004-04-01 2008-03-26 北京安波特基因工程技术有限公司 基因工程重组抗cea抗cd3抗cd28线性单链三特异抗体
AU2006321888A1 (en) * 2005-12-08 2007-06-14 University Of Louisville Research Foundation, Inc. Immunostimulatory compositions and methods
US20080003225A1 (en) 2006-06-29 2008-01-03 Henri Vie Method for enhancing the antibody-dependent cellular cytotoxicity (ADCC) and uses of T cells expressing CD16 receptors
US8865169B2 (en) 2007-02-20 2014-10-21 Tufts University Methods and systems for multi-antibody therapies
JP2012501180A (ja) * 2008-08-26 2012-01-19 シティ・オブ・ホープ Ｔ細胞の抗腫瘍エフェクター機能増進のための方法および組成物
CA2742777A1 (en) 2008-11-06 2010-05-14 University Of Guelph Methods of improving the therapeutic efficacy and utility of antibody fragments
US8465743B2 (en) 2009-10-01 2013-06-18 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-vascular endothelial growth factor receptor-2 chimeric antigen receptors and use of same for the treatment of cancer
EP2651442B1 (en) 2010-12-14 2020-04-22 University of Maryland, Baltimore Universal anti-tag chimeric antigen receptor-expressing t cells and methods of treating cancer
US9708384B2 (en) 2011-09-22 2017-07-18 The Trustees Of The University Of Pennsylvania Universal immune receptor expressed by T cells for the targeting of diverse and multiple antigens

Also Published As

Publication number Publication date
US20160129109A1 (en) 2016-05-12
CA3102782A1 (en) 2012-06-21
EP2651442A2 (en) 2013-10-23
EP3693017A1 (en) 2020-08-12
CA2821080A1 (en) 2012-06-21
US20210330769A1 (en) 2021-10-28
US10973893B2 (en) 2021-04-13
WO2012082841A9 (en) 2012-08-09
US9233125B2 (en) 2016-01-12
US20130287752A1 (en) 2013-10-31
US20240299517A1 (en) 2024-09-12
EP2651442B1 (en) 2020-04-22
AU2011343887B2 (en) 2016-06-16
JP2014504294A (ja) 2014-02-20
ES2791716T3 (es) 2020-11-05
WO2012082841A2 (en) 2012-06-21
EP2651442A4 (en) 2016-06-01
US12005103B2 (en) 2024-06-11
AU2011343887A1 (en) 2013-07-04
CA2821080C (en) 2021-02-02

Similar Documents

Publication Publication Date Title
JP5897035B2 (ja) 汎用の抗タグキメラ抗原受容体発現ｔ細胞及びがんを治療する方法
JP7660382B2 (ja) 多様な多重抗原のターゲティングのための汎用的キメラ抗原受容体を発現する免疫細胞および該免疫細胞の製造方法ならびに該免疫細胞の、癌、感染症および自己免疫疾患の治療のための使用
EP3581200A1 (en) Reversed universal chimeric antigen receptor expressing immune cells for targeting of diverse multiple antigens and method of manufacturing the same and use of the same for treatment of cancer, infections and autoimmune disorders
US10071118B2 (en) Compositions and methods for treating peritoneal cancers
US20240254183A1 (en) Membrane-bound il-12 for cellular immunotherapy
RU2824391C2 (ru) Иммунные клетки, экспрессирующие обратный универсальный химерный антигенный рецептор, для нацеливания на различные многочисленные антигены и способ их получения и применения для лечения рака, инфекций и аутоиммунных заболеваний
HK40068149A (en) Universal chimeric antigen receptor expressing immune cells and method of manufacturing the same and the therapeutic use of the same

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140523

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20140523

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150512

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150810

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150908

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20151009

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20160209

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20160301

R150 Certificate of patent or registration of utility model

Ref document number: 5897035

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250